Astex Pharmaceuticals Inc, a subsidiary of Otsuka Pharmaceutical Co Ltd, has received approval from the United States Food and Drug Administration (FDA) for its Inqovi (decitabine and cedazuridine) tablets intended for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia, it was reported on Tuesday.
The medicine is taken at home as one tablet orally once daily for five consecutive days of each 28-day cycle. This represents an important advance in treatment options for patients with MDS, a type of blood cancer, who previously needed to visit a health care facility to receive intravenous therapy.
The product received approval based on clinical trial results that indicated similar drug concentrations between intravenous decitabine and Inqovi. The US FDA has granted this application priority review status.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT